Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil Safety and Effectiveness in Japanese Women
NCT01544478Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), Cervical Cancer (CC), sponsored by Merck & Co.. Started Nov 2011; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)adenocarcinoma in situ (AIS)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01544478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01544478.